# Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19

> **NCT05065645** · PHASE1 · COMPLETED · sponsor: **Apeiron Biologics** · enrollment: 40 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Angiotensin Converting Enzyme 2
- **DRUG:** Sodium chloride

## Key facts

- **NCT ID:** NCT05065645
- **Lead sponsor:** Apeiron Biologics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-19
- **Primary completion:** 2022-05-27
- **Final completion:** 2022-05-27
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05065645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05065645, "Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05065645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*